Endovascular Engineering, Inc. (E2) is a mission-driven, venture-backed company focused on developing next-generation clot removal technologies targeting venous thromboembolism. Their key product, the Hēlo™ PE Thrombectomy System, utilizes a unique funnel design and dual-action technology for effective clot engagement and removal. The company differentiates itself through innovative design that combines the benefits of large and small-bore embolectomy, aiming to reduce patient risk while improving outcomes. As a preclinical stage company, they are actively engaged in clinical trials to validate their technology and establish a strong market position in the medical device industry.

Is this your company?